数据链接：
官方服务：
资源简介：
Responses of 19 AML patients enrolled in the study.
应用场景：
创建时间：
2024-07-25
相关数据集
Impact of acute lymphoblastic leukemia induction therapy: findings from metabolomics on non-fasted plasma samples from a biorepository
INTRODUCTION: Acute lymphoblastic leukemia (ALL) is among the most common cancers in children. With improvements in combination chemotherapy regimens, the overall survival has increased to over 90%. H
NIAID Data Ecosystem60
Patient characteristics and clinical outcome.
Response corresponds to the best response of the treated lesions observed during the study. Duration of response: Number of days between the documented best response (CR, PR, MR) of treated lesions un
Figshare2015-12-02 更新40
Expression data for pharmacogenomics antiplatelet therapy
Antiplatelet therapy is the most important treatment to reduce the risk of developing recurrent thrombosis, and to prevent progression to a complete occlusion of coronary arterial disease (CAD) patien
NIAID Data Ecosystem30
Clinical features and pharmacological treatment of ASA-sensitive and ASA-resistant patients undergoing to in vitro stimulation to collagen.
ACE: angiotensin-converting enzyme. CT: closure time. The results of categorical variables are represented as number of cases with respect to the total included patients within each experimental group
Figshare2015-12-02 更新40
A methylation signature at diagnosis in patients with high-risk Myelodysplastic Syndromes and secondary Acute Myeloid Leukemia predicts azacitidine response but not relapse. A methylation signature at diagnosis in patients with high-risk Myelodysplastic Syndromes and secondary Acute Myeloid Leukemia predicts azacitidine response but not relapse
Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not sui
NIAID Data Ecosystem30
